RB1 and triple-negative breast carcinoma: Wang et al. found that the Rb-E2F1 axis which was a crucial compound in the cell cycle was regulated by CENPF to improve the drug sensitivity in chemotherapy of triple-negative breast cancer (Wang et al., 2023).